Mehmet Copur, MD
Hematology & Oncology · Grand Island, NENPI 1871517433
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (44.1%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Amgen at 24.4% of the total. Reporting peaked in 2019 at $6,951 and has fallen 57.0% since, to $2,986 in 2025.
Across 695 payments — averaging $36.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$6K
- Array Biopharma Inc$3K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Gilead$2K
- Pfizer$1K
- Seagen Inc.$1K
- plus $10K from 54 others
Across 16 payments — averaging $1604.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Karyopharm Therapeutics Inc.$10K
- Incyte Corporation$9K
- Merck$4K
- Amgen$1K
- Pharmacyclics LLC, An Abbvie Company$750
- F. Hoffmann-la Roche AG$478
What the payments were for
- Consulting fees$8,26533%
- Speaking & faculty fees$2,60010%
- Travel & lodging$1,2845%
- Food & beverage$11,10144%
- Education$1,9298%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kyprolis$5,833
- BRAFTOVI$2,400
- ALUNBRIG$2,145
- QINLOCK$400
- Monoferric$195
How this compares
$25,179 in reported general payments places this provider in the 80th percentile of 73 hematology & oncology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 40 | $512,663 |
| CabometyxCabozantinib S-Malate | 17 | $404,100 |
| ScemblixAsciminib Hydrochloride | 13 | $272,290 |
| ImbruvicaIbrutinib | 16 | $239,516 |
| JakafiRuxolitinib Phosphate | 14 | $219,974 |
| BrukinsaZanubrutinib | 14 | $210,713 |
| TalzennaTalazoparib Tosylate | 11 | $182,167 |
| CalquenceAcalabrutinib Maleate | 16 | $165,974 |
| XtandiEnzalutamide | 11 | $144,734 |
| XareltoRivaroxaban | 58 | $51,689 |
| EliquisApixaban | 14 | $8,207 |
| Letrozole | 281 | $5,643 |
| ZenpepLipase/Protease/Amylase | 20 | $4,080 |
| Exemestane | 24 | $1,216 |
| Anastrozole | 34 | $856 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Exelixis Inc.Cabometyx | $234 | $404,10017 claims |
| NovartisScemblix | $685 | $272,29013 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $287 | $239,51616 claims |
| Incyte CorporationJakafi | $438 | $219,97414 claims |
| PfizerTalzenna, Eliquis | $1,054 | $190,37425 claims |
| AstraZenecaCalquence | $609 | $165,97416 claims |
| Astellas Pharma US IncXtandi | $595 | $144,73411 claims |
| Johnson & JohnsonXarelto | $550 | $51,68958 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 73 hematology & oncology providers in Nebraska.
Other hematology & oncology in Grand Island
- Sarah CreamerGrand Island$4K
- Ryan RamaekersGrand Island$2K
- Mojtaba AkhtariOmaha$1.8M
- Rabih FahedNorfolk$294K
- Luke NordquistOmaha$202K
- Apar Kishor GantiOmaha$138K
- Julie VoseOmaha$123K
- Peter SilbersteinOmaha$99K
- Krishna GundaboluOmaha$76K
- Vijaya BhattOmaha$58K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.